TY - JOUR
T1 - Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy
AU - Yetkin-Arik, Bahar
AU - Kastelein, Arnoud W.
AU - Klaassen, Ingeborg
AU - Jansen, Charlotte H. J. R.
AU - Latul, Yani P.
AU - Vittori, Miloš
AU - Biri, Aydan
AU - Kahraman, Korhan
AU - Griffioen, Arjan W.
AU - Amant, Frederic
AU - Lok, Christianne A. R.
AU - Schlingemann, Reinier O.
AU - van Noorden, Cornelis J. F.
N1 - Funding Information: This study was supported financially by the following foundations: BYA, IK, ROS: Landelijke Stichting voor Blinden en Slechtzienden , Algemene Nederlandse Vereniging ter Voorkoming van Blindheid , Stichting Blinden-Penning , Stichting Oogfonds Nederland, MaculaFonds, that all contributed through UitZicht (Grant 2018-26 , 2017-29 and 2015-19 ), Stichting tot Verbetering van het Lot der Blinden , Rotterdamse Stichting Blindenbelangen (Grant B20140049 ), Stichting voor Ooglijders , Stichting Blindenhulp . This study was published with the help of the Edmond en Marianne Blaauw Fonds voor Oogheelkunde. MV and CJFvN were supported by a research grant of the Slovenian Research Agency (ARRS), grant number J3-2526 . The funding organizations had no role in the design or conduct of this research. They provided unrestricted grants. Funding Information: This study was supported financially by the following foundations: BYA, IK, ROS: Landelijke Stichting voor Blinden en Slechtzienden, Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Stichting Blinden-Penning, Stichting Oogfonds Nederland, MaculaFonds, that all contributed through UitZicht (Grant 2018-26, 2017-29 and 2015-19), Stichting tot Verbetering van het Lot der Blinden, Rotterdamse Stichting Blindenbelangen (Grant B20140049), Stichting voor Ooglijders, Stichting Blindenhulp. This study was published with the help of the Edmond en Marianne Blaauw Fonds voor Oogheelkunde. MV and CJFvN were supported by a research grant of the Slovenian Research Agency (ARRS), grant number J3-2526. The funding organizations had no role in the design or conduct of this research. They provided unrestricted grants. Publisher Copyright: © 2020 The Authors
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a major focus of fundamental and clinical research. However, survival benefits of current anti-angiogenic agents, such as bevacizumab, in patients with gynecological cancer, are modest. Therefore, a better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies, either or not in combination with other therapeutic approaches. We describe the molecular aspects of (tumor) blood vessel formation and the tumor microenvironment and provide an extensive clinical overview of current anti-angiogenic therapies for gynecological cancers. We discuss the different phenotypes of angiogenic endothelial cells as potential therapeutic targets, strategies aimed at intervention in their metabolism, and approaches targeting their (inflammatory) tumor microenvironment.
AB - Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a major focus of fundamental and clinical research. However, survival benefits of current anti-angiogenic agents, such as bevacizumab, in patients with gynecological cancer, are modest. Therefore, a better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies, either or not in combination with other therapeutic approaches. We describe the molecular aspects of (tumor) blood vessel formation and the tumor microenvironment and provide an extensive clinical overview of current anti-angiogenic therapies for gynecological cancers. We discuss the different phenotypes of angiogenic endothelial cells as potential therapeutic targets, strategies aimed at intervention in their metabolism, and approaches targeting their (inflammatory) tumor microenvironment.
KW - Angiogenesis
KW - Anti-angiogenic therapy
KW - Endothelial cell metabolism
KW - Endothelial cells
KW - Gynecological cancer
KW - Non-tip cells
KW - Tip cells
KW - Tumor microenvironment
KW - Vascular disrupting agents
UR - http://www.scopus.com/inward/record.url?scp=85094948866&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.bbcan.2020.188446
DO - https://doi.org/10.1016/j.bbcan.2020.188446
M3 - Review article
C2 - 33058997
SN - 0304-419X
VL - 1875
JO - BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
JF - BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
IS - 1
M1 - 188446
ER -